Suppr超能文献

血清细胞纤连蛋白和基质金属蛋白酶-9作为急性缺血性卒中溶栓治疗后实质内血肿预测的筛查生物标志物:一项多中心验证性研究。

Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study.

作者信息

Castellanos Mar, Sobrino Tomás, Millán Mónica, García María, Arenillas Juan, Nombela Florentino, Brea David, Perez de la Ossa Natalia, Serena Joaquín, Vivancos José, Castillo José, Dávalos Antoni

机构信息

Department of Neurology, Hospital Universitari Doctor Josep Trueta, Girona, Spain.

出版信息

Stroke. 2007 Jun;38(6):1855-9. doi: 10.1161/STROKEAHA.106.481556. Epub 2007 May 3.

Abstract

BACKGROUND AND PURPOSE

Plasma levels of cellular fibronectin (c-Fn) > or =3.6 microg/mL and of matrix metalloproteinase-9 (MMP-9) > or =140 ng/mL have been associated with parenchymal hematoma (PH) after treatment with tissue-type plasminogen activator (t-PA) in patients with acute ischemic stroke. In this prospective study, we sought to validate the predictive capacity of the preestablished cutoff values of these biomarkers for PH in a larger series of patients.

METHODS

We studied 134 patients treated with t-PA within 3 hours from symptom onset according to the SITS-MOST criteria (median time to infusion, 152 minutes; median National Institutes of Health Stroke Scale score, 14) in 4 university hospitals. Hemorrhagic transformation was classified according to the European-Australasian Acute Stroke Study II definitions on computed tomography scans performed 24 to 36 hours after treatment. Relevant hemorrhagic transformation was defined as hemorrhagic infarction type 2 or any PH. Serum c-Fn and MMP-9 levels were determined by an ELISA om blood samples obtained before treatment.

RESULTS

Cranial computed tomography showed hemorrhagic transformation in 27 patients (20%), hemorrhagic infarction in 15 (type 2 in 8 patients), and PH in 12 patients (symptomatic in 4). Serum c-Fn and MMP-9 concentrations at baseline were significantly higher in patients with relevant hemorrhagic transformation and PH than in those without (all P<0.001). The sensitivity, specificity, and positive and negative predictive values for PH by c-Fn levels > or =3.6 microg/mL were 100%, 60%, 20%, and 100%, respectively, whereas corresponding values were 92%, 74%, 26%, and 99% for MMP-9 levels > or =140 ng/mL. When both biomarkers were at levels above the cutoff points, specificity increased to 87% and the positive predictive value increased to 41%.

CONCLUSIONS

This prospective study confirmed the high sensitivity and negative predictive value, with retained good specificity, of c-Fn and MMP-9 for the prediction of PH in patients treated with t-PA. Development of faster analytic methods will prove the applicability of these biomarkers in routine clinical practice.

摘要

背景与目的

在急性缺血性脑卒中患者接受组织型纤溶酶原激活剂(t-PA)治疗后,血浆细胞纤连蛋白(c-Fn)水平≥3.6μg/mL以及基质金属蛋白酶-9(MMP-9)水平≥140 ng/mL与实质血肿(PH)相关。在这项前瞻性研究中,我们试图在更大系列的患者中验证这些生物标志物预先设定的临界值对PH的预测能力。

方法

我们在4所大学医院对134例根据SITS-MOST标准在症状发作后3小时内接受t-PA治疗的患者进行了研究(输注的中位时间为152分钟;美国国立卫生研究院卒中量表评分中位数为14)。根据欧洲-澳大利亚急性卒中研究II的定义,在治疗后24至36小时进行的计算机断层扫描上对出血性转化进行分类。相关出血性转化定义为2型出血性梗死或任何PH。通过酶联免疫吸附测定法(ELISA)测定治疗前采集的血液样本中的血清c-Fn和MMP-9水平。

结果

头颅计算机断层扫描显示27例患者(20%)出现出血性转化,15例出现出血性梗死(8例为2型),12例出现PH(4例有症状)。有相关出血性转化和PH的患者基线时血清c-Fn和MMP-9浓度显著高于无相关情况的患者(所有P<0.001)。c-Fn水平≥3.6μg/mL对PH的敏感性、特异性、阳性预测值和阴性预测值分别为100%、60%、20%和100%,而MMP-9水平≥140 ng/mL时相应的值分别为92%、74%、26%和99%。当两种生物标志物水平均高于临界值时,特异性增至87%,阳性预测值增至41%。

结论

这项前瞻性研究证实,c-Fn和MMP-9对接受t-PA治疗患者的PH预测具有高敏感性和阴性预测值,同时保留了良好的特异性。开发更快的分析方法将证明这些生物标志物在常规临床实践中的适用性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验